T
he SWI͞SNF family of genes, which encode a group of chromatin remodeling engines, have recently been implicated as playing a role in cancer (1) (2) (3) . Membership in the SWI͞SNF superfamily is defined by a structure of seven DNAdependent ATPase motifs that is conserved in organisms from yeast to humans, and as members of multiprotein complexes SWI͞SNF proteins use the energy of ATP hydrolysis to alter nucleosome position or spacing (4, 5) . In addition to chromatin reorganization, SWI͞SNF-related proteins have been implicated in many aspects of cellular function, including maintenance of chromosome stability and proper chromosome segregation (lodestar) (6) , recombination (RAD54 and RAD54b), nucleotide excision repair (RAD4, ERCC6, and RAD16) (7), and transcriptional activation or repression (MOT1 and HLTF) (8) (9) (10) (11) . Although most SWI͞SNF proteins lack specific DNAbinding motifs and are thought to contribute to transcriptional activation by perturbing chromatin structure to allow promoter access for sequence-specific activator proteins, select members of the SWI͞SNF family, such as CHD1 and HLTF (helicase-like transcription factor, also called HIP116a, Zbu1, RUSH1a, and Smarca3) have sequence-specific DNA-binding domains and so can be targeted to specific promoters directly (9, 12, 13) .
Recently, mutations of some SWI͞SNF family genes were reported in cancers. Human hSNF5͞INI1 gene was found to be inactivated frequently in pediatric malignant rhabdoid tumors (3), meningiomas (2) , and lymphoid tumors (14) . BRG1 inactivation mutations have been reported in human prostate, breast, pancreas, and lung tumor cell lines (15) , whereas mutations of RAD54b were reported in human primary lymphoma and colon cancer (1) , suggesting that SWI͞SNF genes can function as tumor suppressor genes.
In this study, we evaluated HLTF, a SWI͞SNF family member gene, as a candidate target for inactivation in cancers. We report here that the HLTF gene was specifically silenced by hypermethylation in 43% of colon cancers. In contrast, no gene silencing was observed in lung or breast samples tested. In addition, transfection of HLTF suppressed colony-forming ability of HLTF-deficient, but not HLTF-proficient, colon cancer cells. HLTF is thus a common target for methylation and epigenetic gene silencing in colon cancer and is a candidate colon cancer suppressor gene. treated with 5-azaC as described (19) . The optimal tolerated 5-azaC doses were determined for each treated line, and two doses were used for some lines, ranging from 1 g͞ml to 3 g͞ml.
Clonogenic Assays and Transfections. Cells were plated in 6-well dishes (12,000-20,00 cells͞well) 24 h before transfection in regular growth medium and transfected with 0.4 g DNA͞well with effectene (Qiagen, Chatsworth, CA) according to the manufacturer's protocol. G418 was added to the wells 48 h after transfection, and cells were kept in G418 media (replaced biweekly) for 3 weeks, until tight colonies were observed. Colonies were stained with trypan blue and counted. In the process of HLTF sequence analysis in colon cancer cell lines we noted that nine of 34 cell lines did not express HLTF cDNA (Fig. 1A and data not shown) . Southern analysis did not identify any alterations in the HLTF locus. Coincidentally, in some of the cell lines that had lost HLTF expression we previously had demonstrated silencing of the hMLH1 gene caused by promoter methylation (19) . We therefore examined the genomic sequence upstream of the HLTF (GenBank accession no. NT005616) where we identified a putative HLTF promoter that we noted indeed contained a CpG dense region that could potentially be methylated ( Fig. 2A) . No TATA box consensus sequence was found within the putative promoter. However, it did contain a consensus initiator element and two SP1 sites that are typical of TATA-less housekeeping gene promoters.
To test for methylation of the CpG-rich region of the putative HLTF promoter, we used MS-PCR (16), using PCR primers specific for amplification of either methylated or unmethylated DNA templates (Fig. 2 A) . As shown in Fig. 2B , all colon cancer cell lines that lacked HLTF gene expression demonstrated methylation of CpG sites within the putative HLTF promoter; whereas, methylation was not detected in the HLTF-expressing cell lines. These results were confirmed by two independent MS-PCR assays that tested different HLTF promoter CpG sites, as well as by resistance of the HLTF promoter to digestion with a methylation-sensitive restriction enzyme, HpaII (data not shown). Thus, cell lines that had silenced the HLTF gene demonstrated methylation that spanned the entire HLTF promoter-associated CpG island, whereas HLTF-expressing cell lines assayed as free of methylated CpG sites.
For three of these HLTF-methylated cell lines (V6, V8, and V432), DNA from matched normal and antecedent tumor DNA was additionally available. In each of these cases, HLTF promoter methylation was detected in the primary tumors, but was absent in the matched normal tissues (Fig. 2C ), verifying that HLTF methylation and silencing was a true somatic event and was not an artifact of cell line culture.
Reinduction of HLTF Expression. To establish that methylation was responsible for silencing HLTF gene expression, cell lines with HLTF promoter methylation were treated with 5-azaC, a demethylating agent. In each of the seven cell lines tested, HLTF expression was strongly reactivated by 5-azaC treatment (Fig. 1B , plus data not shown). However, 5-azaC did not alter HLTF expression in control cell lines in which HLTF expression was constitutive and in which the basal HLTF promoter was unmethylated. In five of the cell lines in which 5-azaC treatment induced re-expression of HLTF, the re-expressed transcripts were PCRamplified and sequenced. In all five cases, the sequencing confirmed that the re-expressed HLTF allele was wild type. However, in three of these cases the presence of common silent HLTF sequence polymorphisms enabled us to recognize that 5-azaC had reactivated expression of two distinguishable HLTF alleles, of presumptive maternal and paternal origin, both of which had been independently silenced by methylation. Thus aberrant methylation would appear to be an efficient and preferred mechanism for inactivation of the HLTF gene (which maps to cytogenetic position 3q25.1-26.1; ref. 20) .
HLTF Methylation Is Widespread in Primary Colon
Cancer. To further establish the frequency of HLTF methylation in primary colon cancer tumors, we analyzed an additional 63 pairs of primary colon tumors along with matched normal tissues ( Fig. 3 and data not shown). HLTF methylation was detected in 27 of 63 (43%) primary colon cancers. In contrast, no evidence of HLTF gene silencing was detected in 30 lung cancer cell lines or eight breast cancer samples tested (data not shown).
The finding of HLTF methylation in colon cancer tumors and cell lines was not significantly correlated with patients' sex (P ϭ 0.31) or age (P ϭ 0.14), with a median age of 72 in persons with HLTF-methylated cancers versus 68 in those with HLTFunmethylated cancers. In the overwhelming majority of cases (84%), HLTF methylation was detected only in the colon cancers and was absent from the same individuals' normal colon tissues. HLTF methylation thus substantially arose in these individuals specifically during the neoplastic process. In the uncommon cases in which methylation was detected in normal colon tissue, the signal was very faint. Surveying 78 normal colon tissues recovered from cancer resections, we detected such faint HLTF methylation in 12% of cases (nine of 78), with individuals showing such methylation having a median age of 81 compared with 67 for those demonstrating unmethylated HLTF only (P ϭ 0.02). Compared with HLTF-expressing cancers, cancers with methylated and silenced HLTF alleles showed a borderline significant trend (P ϭ 0.06) to be more likely to arise in the proximal right colon and less likely to arise in the rectum, a trend similar to that previously observed for hereditary nonpolyposis colon cancer and sporadic microsatellite instability colon cancer (21) ( Table 1) . The distribution by tumor stage (adenoma; Dukes' stage B, C, or D cancer primary; or metastatic lesion) was also significantly different between HLTF-methylated and nonmethylated colon neoplasms (P ϭ 0.02) ( Table 2 ). An a postiori grouping of the tumors into metastatic (Dukes' D primary cancers plus cancers from distant metastatic sites) versus nonmetastatic subsets suggests the hypothesis that this difference is caused by a lesser likelihood of HLTF-methylated tumors being metastatic (nominal P value ϭ 0.01).
To determine the timing of onset of HLTF silencing during colon carcinogenesis, we additionally analyzed a group of 28 early and late adenomas for HLTF CpG island methylation. HLTF methylation was detected in seven of the adenomas, all of which were larger than 1.5 cm in size and͞or demonstrated villous histology, suggesting that HLTF methylation commences at the advanced adenoma stage of colon neoplasia. 
HLTF Methylation Defines a Singular Group of Colon Cancers.
Recently, it has been suggested that certain colon cancers are typified by a high frequency of gene promoter methylation and represent a distinct pathway termed CIMPϩ (22, 23) . Tumors exhibiting this phenotype (CIMPϩ) show concordant CpG island methylation affecting multiple genes, including hMLH1, p16, and THBS1. To establish whether HLTF methylation correlates with hMLH1 methylation, and͞or with CIMPϩ, 87 colon cancer cases examined for HLTF methylation were also examined for hMLH1 methylation, and 63 were further assayed for CIMPϩ or CIMPϪ as determined by methylation status of two or more of MINT1, MINT2, MINT31, and MINT27 loci (22) . HLTF methylation correlated with CIMPϩ (P Ͻ 0.001) ( Table  3 ) and as well with hMLH1 gene methylation (P Ͻ 0.0001) ( Table  4) . However, HLTF-methylated tumors essentially defined a distinct subclass of colon cancers that did not fall exclusively into either the hMLH1-methylated or CIMPϩ groups (Fig. 4) . This finding suggests that aberrant methylation of HLTF might involve at least in part a mechanism distinct from that leading to the CIMPϩ or hMLH1 gene methylation, and͞or that the current assay for CIMPϩ may not be 100% sensitive for recognizing all cancers in which an underlying hypermethylation defect is present.
To further determine whether HLTF methylation defines a singular group of colon cancers, we used restriction landmark genomic scanning (RLGS) analysis (24) to compare the patterns of global genome methylation in a group of 12 colon cancer cell lines, six of which demonstrated HLTF methylation and silencing and in six of which HLTF was unmethylated and expressed. A total of 497 loci demonstrated methylation present in at least one of the 12 colon cancer cell lines (D.S., unpublished data). However, none of these loci demonstrated a pattern of methylation matching that of HLTF. That is, no other locus demonstrated the presence of methylation across the six colon cancers in which HLTF was methylated and silenced, plus the absence of methylation across the six colon cancers in which HLTF was unmethylated and expressed. Although RLGS analysis samples only a portion of the genome, these data independently suggest the uniqueness of HLTF methylation, and the potential that if hypermethylated tumors derive from a general class they may also potentially evolve along multiple distinct pathways.
HLTF Reconstitution Induces Growth Suppression. The high frequency of HLTF methylation observed in colon cancer suggested that inactivation of this gene might confer a selective advantage.
To assay for such an advantage we examined the effect of HLTF transfection on colony formation in three HLTF-methylated and nonexpressing colon cancer cell lines (V457, V8-2, and RCA) as compared with three HLTF unmethylated and HLTF-expressing colon cancer cell lines (FET, V364, and V429). Reconstitution of HLTF expression in HLTF-methylated cells suppressed colony-forming ability by 75% in each of the three lines tested (P Ͻ 0.0001 for each) (Fig. 5B) . In contrast, transfection of HLTF did not show significant colony suppression in the any of the three cell lines that already expressed endogenous HLTF (Fig. 5A) . Growth suppression by exogenous HLTF was thus specific to colon cancers that had silenced the endogenous alleles (P Ͻ 0.01 for the difference in effect of HLTF transfection in HLTF-methylated versus unmethylated cell lines). Transient transfections showed that both HLTF-methylated and unmethylated cells were well able to express exogenous HLTF, as determined by Western analysis for a V5 epitope tag attached to HLTF in the expression vector (Fig. 5C ). These findings suggest that HLTF methylation and silencing indeed confers a growth advantage in a distinct subclass of colon cancers.
Discussion
In this study, we have identified HLTF, a SWI͞SNF family gene, as a target gene for methylation and silencing in human colon cancer. HLTF locus methylation was detected in 43% of primary tumors, suggesting that the inactivation of HLTF gene is a frequent event in the process of tumorogenesis in the colon. The methylation of the HLTF promoter region was associated with loss of HLTF gene expression in colon cancer cell lines. Moreover, transfection of HLTF suppresses growth of HLTF-deficient colon cancers, but does not alter growth of HLFT-proficient cancers. These observations suggest that HLTF silencing may confer a growth advantage on some colon cancers, and hence that HLTF may be a colon cancer tumor suppressor gene. No loss of HLTF expression was seen in lung cancer or breast cancer samples that were also examined, consistent with HLTF silencing being a specific event selected for in colon cancer.
Alterations of DNA methylation patterns are widely documented in human neoplasia. Cancerous cells, as compared with normal tissues, frequently show global genome hypomethylation accompanied by regional increases in DNA methylation that are often within CpG-dense promoter regions of specific genes (25) . In those colon cancers that show hMLH1 gene promoter methylation and silencing, the somatic hMLH1 methylation plays a causal event in carcinogenesis, as it induces microsatellite instability and perfectly recapitulates the effects of hMLH1 germ-line mutations in kindreds with the syndrome of hereditary nonpolyposis colon cancer (19, 26) . In other instances, such as the methylation in some colon cancers of p16 (27, 28) , the established tumor suppressor properties of p16 in noncolonic cancers are strongly suggestive of a direct contribution to colon cancer pathogenesis. In yet other instances, for example the estrogen receptor, a high rate of age-associated methylation and the absence of clear colon cancer tumor suppressor activity suggest that promoter methylation may be an accompaniment rather than a cause of colon carcinogenesis (29) . We did not detect mutational inactivation of HLTF in colon cancer; however, the high frequency of HLTF methylation, the finding of growth suppression by HLTF, the emerging role of other SWI͞SNF family genes in human cancer, and the general absence of HLTF methylation in normal colon when detected in colon cancer all are supportive of HLTF inactivation contributing directly to colon carcinogenesis. The SWI͞SNF gene family of chromatin remodeling engines has been associated with both gene transcription and gene silencing, and elucidating downstream targets for HLTF function may provide further evidence for its playing such a direct role in colon cancer.
HLTF promoter methylation correlated strongly with CIMPϩ. However, unlike colon cancers that demonstrate methylation of the p16 and hMLH1 promoters, which are associated almost exclusively with the CIMPϩ tumor class, a significant number of HLTF-methylated tumors fall into the CIMPϪ group. It is unclear at this point whether this represents two different subsets of tumors with potentially different underlying predispositions for aberrant methylation of the HLTF locus. We noted that a 300-bp fragment of an Alu repeat is present 2 kb upstream of the putative HLTF promoter, and that in normal colon tissue this repeat is heavily methylated (W.C., unpublished data). It is possible that this structure may act as a methylation center from which in some cells methylation spreads outward to the adjacent HLTF promoter.
Age-related methylation in various normal tissues, including colon, has been reported for a number of genes, including ER, MYOD1, IGF1, and N33 (30) . Weak methylation of the HLTF locus also was detected in a small subset of normal tissues, mostly in older individuals (median age of 81 years), indicating that the HLTF locus can be silenced during aging in some colon cells of some individuals. As aging is one of the predisposing factors for many cancers, it has been suggested that, at least for some genes, age-related methylation in a precancerous cell could be an early event leading to tumorigenesis, for example by silencing a tumor suppressor gene and thus conferring a selective growth advantage (30) . Although we cannot exclude a similar mechanism for HLTF gene, our data indicate that in general HLTF methylation happens subsequent to cancer initiation, most likely in advanced adenomas or frank carcinomas, suggesting that perhaps agerelated methylation and HLTF gene silencing in cancers are independent events.
HLTF methylation was observed with a higher frequency in proximal colon and was very rarely observed in rectal cancers. This observation is similar to the previously reported association of CIMPϩ and hMLH1 methylator phenotypes with proximal tumors and may reflect increased exposure of the proximal colon to certain classes of carcinogens (29) . 
